利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

93 条记录 (耗时 0.045 秒)

    Cell Death Inducing Agents
    1.
    发明申请
    Cell Death Inducing Agents 审中-公开
    细胞死亡诱导剂

    公开(公告)号：US20070280951A1

    公开(公告)日：2007-12-06

    申请号：US10582304

    申请日：2004-12-10

    申请人： Naoki Kimura ,  Masayuki Tsuchiya ,  Masahiko Nanami ,  Takashi Tomimatsu ,  Shigeto Kawai

    发明人： Naoki Kimura ,  Masayuki Tsuchiya ,  Masahiko Nanami ,  Takashi Tomimatsu ,  Shigeto Kawai

    IPC分类号： A61K39/395 ,  A61P35/00 ,  A61P37/00 ,  C07H21/00 ,  C07K16/00 ,  C12N1/00 ,  C12N15/63 ,  C12N5/00 ,  C12P21/00

    CPC分类号： C07K16/00 ,  C07K2317/622 ,  C07K2317/73

    摘要： The present inventors constructed a DNA expression vector encoding 2D7sc(Fv)2 in which the heavy chain variable region sequence (VH) and the light chain variable region sequence (VL) of the 2D7 antibody is arranged in the order of VH-VL-VH-VL, and these sequences are linked by a 15-mer linker. The vector was introduced into CHO cells and a 2D7sc(Fv)2-producing expression cell line was established. When 2D7sc(Fv)2 was expressed in this cell line, purified, and cell death-inducing experiments performed, 2D7sc(Fv)2 was found to have a concentration-dependent cell death-inducing activity.

    摘要翻译： 本发明人构建了编码2D7sc（Fv）2的DNA表达载体，其中2D7抗体的重链可变区序列（VH）和轻链可变区序列（VL）以VH-VL-VH -VL，并且这些序列通过15聚体连接子连接。 将载体导入CHO细胞，并建立产生2D7sc（Fv）2的表达细胞系。 当在该细胞系中表达2D7sc（Fv）2时，发现2D7sc（Fv）2的纯化和细胞死亡诱导实验具有浓度依赖性细胞死亡诱导活性。

    Cell death-inducing agent
    2.
    发明申请
    Cell death-inducing agent 失效
    细胞死亡诱导剂

    公开(公告)号：US20060275301A1

    公开(公告)日：2006-12-07

    申请号：US10530696

    申请日：2003-10-10

    申请人： Shuji Ozaki ,  Masahiro Abe ,  Masayuki Tsuchiya ,  Naoki Kimura ,  Shigeto Kawai

    发明人： Shuji Ozaki ,  Masahiro Abe ,  Masayuki Tsuchiya ,  Naoki Kimura ,  Shigeto Kawai

    IPC分类号： A61K39/395 ,  C07K16/30

    CPC分类号： C07K16/2833 ,  A61K2039/505 ,  C07K14/70539 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/626 ,  C07K2317/73

    摘要： To identify antigens of the 2D7 antibody, the present inventors cloned the 2D7 antigen. The results suggested that the 2D7 antigen is an HLA class I molecule. Based on this finding, the present inventors examined whether the 2D7 antibody has cell death-inducing activity. Nuclei fragmentation was observed when the 2D7 antibody was cross-linked with another antibody, indicating that cell-death was induced. Further, diabodies of the 2D7 antibody were found to have very strong cell death-inducing activities, even without the addition of another antibody. These results indicate that minibodies of an HLA-recognizing antibody can be used as cell death-inducing agents.

    摘要翻译： 为了鉴定2D7抗体的抗原，本发明人克隆了2D7抗原。 结果表明，2D7抗原是HLA I类分子。 基于该发现，本发明人检查了2D7抗体是否具有细胞死亡诱导活性。 当2D7抗体与另一种抗体交联时，观察到细胞核碎裂，表明诱导细胞死亡。 此外，发现2D7抗体的双抗体具有非常强的细胞死亡诱导活性，即使没有添加另一种抗体。 这些结果表明HLA识别抗体的小体抗体可以用作细胞死亡诱导剂。

    Cell Death-Inducing Agents
    3.
    发明申请
    Cell Death-Inducing Agents 审中-公开
    细胞死亡诱导剂

    公开(公告)号：US20080274110A1

    公开(公告)日：2008-11-06

    申请号：US11547747

    申请日：2004-04-09

    申请人： Shuji Ozaki ,  Masahiro Abe ,  Masayuki Tsuchiya ,  Naoki Kimura ,  Shigeto Kawai

    发明人： Shuji Ozaki ,  Masahiro Abe ,  Masayuki Tsuchiya ,  Naoki Kimura ,  Shigeto Kawai

    IPC分类号： A61K39/395 ,  C07K16/00 ,  A61P35/04 ,  C12N5/02

    CPC分类号： C07K16/2833 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/73

    摘要： To identify antigens of the 2D7 antibody, the present inventors cloned the 2D7 antigen. As a result, the 2D7 antibody was found to recognize HLA class IA. In addition, the present inventors examined whether the 2D7 antibody has cell death-inducing activity. Nuclei fragmentation was observed when the 2D7 antibody was cross-linked with another antibody, indicating that cell-death was induced. Further, diabodies of the 2D7 antibody were found to have very strong cell death-inducing activities, even without the addition of another antibody. These results indicate that minibodies of an HLA-recognizing antibody can be used as cell death-inducing agents.

    摘要翻译： 为了鉴定2D7抗体的抗原，本发明人克隆了2D7抗原。 结果发现2D7抗体识别HLA类别IA。 此外，本发明人检查了2D7抗体是否具有细胞死亡诱导活性。 当2D7抗体与另一种抗体交联时，观察到细胞核碎裂，表明诱导细胞死亡。 此外，发现2D7抗体的双抗体具有非常强的细胞死亡诱导活性，即使没有添加另一种抗体。 这些结果表明HLA识别抗体的小体抗体可以用作细胞死亡诱导剂。

    Cell death-inducing agent
    4.
    发明授权
    Cell death-inducing agent 失效
    细胞死亡诱导剂

    公开(公告)号：US08158385B2

    公开(公告)日：2012-04-17

    申请号：US10530696

    申请日：2003-10-10

    申请人： Shuji Ozaki ,  Masahiro Abe ,  Masayuki Tsuchiya ,  Naoki Kimura ,  Shigeto Kawai

    发明人： Shuji Ozaki ,  Masahiro Abe ,  Masayuki Tsuchiya ,  Naoki Kimura ,  Shigeto Kawai

    IPC分类号： C12P21/04 ,  C12P21/08

    CPC分类号： C07K16/2833 ,  A61K2039/505 ,  C07K14/70539 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/626 ,  C07K2317/73

    摘要： To identify antigens of the 2D7 antibody, the present inventors cloned the 2D7 antigen. The results suggested that the 2D7 antigen is an HLA class I molecule. Based on this finding, the present inventors examined whether the 2D7 antibody has cell death-inducing activity. Nuclei fragmentation was observed when the 2D7 antibody was cross-linked with another antibody, indicating that cell-death was induced. Further, diabodies of the 2D7 antibody were found to have very strong cell death-inducing activities, even without the addition of another antibody. These results indicate that minibodies of an HLA-recognizing antibody can be used as cell death-inducing agents.

    摘要翻译： 为了鉴定2D7抗体的抗原，本发明人克隆了2D7抗原。 结果表明，2D7抗原是HLA I类分子。 基于该发现，本发明人检查了2D7抗体是否具有细胞死亡诱导活性。 当2D7抗体与另一种抗体交联时，观察到细胞核碎裂，表明诱导细胞死亡。 此外，发现2D7抗体的双抗体具有非常强的细胞死亡诱导活性，即使没有添加另一种抗体。 这些结果表明HLA识别抗体的小体抗体可以用作细胞死亡诱导剂。

    Modified antibodies against cd22 and utilization thereof
    5.
    发明申请
    Modified antibodies against cd22 and utilization thereof 审中-公开
    针对cd22的修饰抗体及其应用

    公开(公告)号：US20070003556A1

    公开(公告)日：2007-01-04

    申请号：US10550934

    申请日：2004-03-31

    申请人： Masayuki Tsuchiya ,  Naoki Kimura ,  Tatsuya Fukuda

    发明人： Masayuki Tsuchiya ,  Naoki Kimura ,  Tatsuya Fukuda

    IPC分类号： A61K39/395 ,  C07K16/30

    CPC分类号： C07K16/2803 ,  C07K2317/622 ,  C07K2317/73

    摘要： CD22 diabodies, in which heavy-chain and light-chain variable regions are linked by a 5-mer linker, were produced based on known sequence information for two types of anti-CD22 antibodies. The two diabodies produced were analyzed for their activity of binding to lymphoma cells and inducing lymphoma cell death (apoptosis). As a result, both diabodies were revealed to bind to the B-lymphoma cell line, “Raji”, and to have apoptosis-inducing activity towards Raji cells as well as towards another B-lymphoma cell line: Daudi cells. These results show that minibodies of antibodies that recognize CD22 can be used as apoptosis-inducing agents for tumor cells such as lymphoma cells.

    摘要翻译： 基于两种类型的抗-CD22抗体的已知序列信息产生CD22双抗体，其中重链和轻链可变区通过5-聚体连接子连接。 分析所产生的两种双抗体与淋巴瘤细胞结合的活性，诱导淋巴瘤细胞死亡（凋亡）。 结果，双抗体被揭示结合到B淋巴瘤细胞系“Raji”，并且对Raji细胞以及另一B淋巴瘤细胞系具有凋亡诱导活性：Daudi细胞。 这些结果表明识别CD22的抗体的小体抗体可以用作肿瘤细胞如淋巴瘤细胞的凋亡诱导剂。

    Method of producing a nucleic acid encoding an antibody
    9.
    发明授权
    Method of producing a nucleic acid encoding an antibody 失效
    生产编码抗体的核酸的方法

    公开(公告)号：US08008076B2

    公开(公告)日：2011-08-30

    申请号：US11587701

    申请日：2005-04-27

    申请人： Masayuki Tsuchiya ,  Masami Suzuki ,  Kenji Yoshida ,  Etsuko Fujii ,  Miho Watanabe ,  Koichi Matsubara ,  Yu Jau Chen ,  Juliana Sim

    发明人： Masayuki Tsuchiya ,  Masami Suzuki ,  Kenji Yoshida ,  Etsuko Fujii ,  Miho Watanabe ,  Koichi Matsubara ,  Yu Jau Chen ,  Juliana Sim

    IPC分类号： C12N15/63 ,  C12N5/06 ,  C12N1/20 ,  C07H21/04

    CPC分类号： A01K67/027 ,  A01K2267/01 ,  A61K35/16 ,  C07K16/00 ,  C07K16/30

    摘要： An objective of the present invention is to facilitate the acquisition of antibody-producing cells that are infiltrating virus-infected cells, cancer cells, abnormal cells forming a benign hyperplasia, and the like, and to improve the efficiency of the production of antibodies as well as nucleic acids encoding them from the antibody-producing cells.The present inventors discovered that, when cancer tissues comprising infiltrating lymphocytes are transplanted into highly immunodeficient animals that do not have T cells, B cells, and NK cells and further exhibit a low IFN production ability, the differentiation and proliferation of infiltrating lymphocytes are unexpectedly promoted, and the number of plasma cells that produce antibodies recognizing cancer tissues increases dramatically, plasma cells can be separated easily, and antibodies or nucleic acids encoding them can be easily prepared from the plasma cells.

    摘要翻译： 本发明的目的是便于获得渗透病毒感染细胞的抗体产生细胞，癌细胞，形成良性增生的异常细胞等，以及提高抗体生产的效率 作为从抗体产生细胞编码它们的核酸。 本发明人发现，当将包含浸润性淋巴细胞的癌组织移植到不具有T细胞，B细胞和NK细胞的高度免疫缺陷的动物中并且进一步表现出低的IFN产生能力时，意外地促进了浸润性淋巴细胞的分化和增殖 并且产生识别癌组织的抗体的浆细胞的数量急剧增加，可以容易地分离浆细胞，并且可以容易地从浆细胞制备抗体或编码它们的核酸。